drugset / Trial / NCT02159729

Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

NCT02159729

Phase 2 Completed 205 enrolled Kythera Biopharmaceuticals
Non-randomizedParallel-groupDouble-blindOther

Summary

This was a long-term follow-up study of participants who completed Kythera-sponsored trials of ATX-101 (06-03, 07-07, 09-15)

Timeline

Start
2009-02
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ATX-101 Peptide 1 unknown
Subject ATX-101 Peptide 2 unknown
Subject ATX-101 Peptide 4 unknown

Indications

No indication recorded.